UNION therapeutics appoints drug development leader Dr. Peter Kristensen to its Board of Directors

• Dr. Peter Kristensen, MD, DMSc, EMBA, appointed new member of UNION’s Board of Directors, bringing more than 25 years of expertise from drug development and regulatory approval from pharmaceutical companies
• Strengthening of the Board of Directors with late-stage drug development expertise follows read-out of three Phase 2/2b studies with orismilast and prior to initiation of Phase 3 studies with orismilast in atopic dermatitis (AD)

Hellerup, Denmark, August 6, 2024 – UNION therapeutics A/S (UNION), a privately held, clinical stage, pharmaceutical development company focused on immunology, today announces that Dr. Peter Kristensen, a clinical development and regulatory approval expert with more than 25 years of leadership expertise from Novo Nordisk has been elected to the Board of Directors of UNION at an extraordinary General Assembly.

“I am pleased to welcome Peter Kristensen to UNION’s Board of Directors”, says Stig Løkke Pedersen, Chair of the Board of Directors at UNION. “With his impressive track record, Peter brings hands-on experience from clinical development and regulatory approval through all phases of drug development. At Novo Nordisk, Peter has been central to the development of GLP-1 analogues, which shares tolerance profile with PDE4 inhibitors like UNION’s orismilast, and together with his broad experience within drug development I believe Peter will be an important addition to the Board of Directors of UNION.”

“I look forward to joining UNION's Board of Directors and working with the UNION team as well as their lead assets, orismilast, a high potency, selective PDE4 B/D inhibitor”, adds Dr. Peter Kristensen, member of the Board of Directors at UNION. “Orismilast has demonstrated significant promise in recent Phase 2 and Phase 2b studies making it a very interesting opportunity to bring a new oral treatment to patients in the field of dermatology and immunology.”

Dr. Peter Kristensen is replacing Dr. Jutta Heim who has been a Board member in UNION for seven years and has been instrumental in bringing the company’s assets through the earlier stages of development.

“As much as I welcome Peter Kristensen to the Board of Directors, I would like to express my deepest gratitude to Jutta Heim for her invaluable contributions to UNION’s Board of Directors, including her vast experience with early-stage research and profiling of compounds”, comments Rasmus Toft-Kehler, Co-CEO and Co-Founder of UNION and continues “Jutta’s insightful contributions and steadfast dedication have been instrumental in building UNION and bringing orismilast ready for Phase 3 development.”

Biography for Dr. Peter Kristensen

Peter brings more than 30 years of drug development and regulatory experience from his employment at Novo Nordisk, as Senior External Advisor with McKinsey & Co and as an independent consultant. At Novo Nordisk, Peter started as a research scientist, headed the development of Victoza (liraglutide) and was for 10+ years Senior Vice President of drug development, project management and global clinical operations. After leaving Novo Nordisk Peter has taken on consulting and board roles, including serving as chairman of the InnoExplorer program at the Innovation Fund Denmark.

Peter has a Medical Degree and a Medical Doctorate from University of Copenhagen, an E*MBA from SIMI (today part of CBS Executive) and is a member of the Danish Academy of Technical Sciences.

Contacts

Morten Boesen, Chief Financial Officer, UNION therapeutics A/S

+45 2381 5487

morten.boesen@uniontherapeutics.com

Sarah Toft-Jørgensen, Director of Communications and IR, UNION therapeutics A/S

+45 5385 3044

sarah.toft-joergensen@uniontherapeutics.com

About UNION therapeutics

UNION therapeutics is a privately held, clinical stage, pharmaceutical development company focused on immunology. UNION’s lead asset is orismilast, a next generation, high potency PDE4 B/D inhibitor, for a range of immunological diseases e.g., atopic dermatitis (AD) and hidradenitis suppurativa. Orismilast holds the potential to become the first safe oral treatment in AD. UNION is headquartered in Hellerup, Denmark, and led by an international team combining biotech entrepreneurs and seasoned pharma executives, with a track record of developing and launching more than fifteen marketed drugs. Read more at www.uniontherapeutics.com